Login
Navigate Fool.com
Will PCRX beat
the market?
Community Rating: 1 Star: Ominous

85.84 0.65 (0.76%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $84.43
Previous Close $85.19
Daily Range $83.30 - $85.97
52-Week Range $30.75 - $94.30
Market Cap $3.1B
P/E Ratio -52.91
Dividend (Yield) $0.00 (0.0%)
Volume 198,759
Average Daily Volume 514,606
Current FY EPS -$0.67

How do you think PCRX
will perform against the market?

Top PCRX Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted August 8, 2011

One of my strategies to come out ahead in the current decline is to find stocks that have been beaten down severely but have potential strong catalysts before the end of the year. Pacira's catalyst is … More

1 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted January 20, 2012

The commercial success of Exparel is a tough call to make. Intuitively, the drug seems to be filling an important niche in post-operative pain management. But empirical evidence tells us that launches … More

2 Replies Reply Report this Post

News & Commentary Rss Feed

3 Stocks With Jaw-Dropping Growth Potential

MiMedx, The Medicines Company, and Pacira Therapeutics should all see huge leaps in their earnings going forward. Here's what you need to know.

New Stock Coverage: Pacira Pharmaceuticals Is Just What the Doctor Ordered

Wall Street ratings agencies set the tone for today's stock market.

Bruised in Market Decline Last Week, Healthcare Stocks Leading Wednesday's Broad-Based Rally

Sector Update: Healthcare

Why Pacira Pharmaceuticals, Inc. Shares Jumped

Pacira Pharmaceuticals shares jump for an unlikely reason, but here's what shareholders should really be watching.

Sector Update: Healthcare Shares Higher Pre-Market; Alkermes up 11% on Phase 3 Trial Results

Sector Update: Healthcare

Why Pacira Pharmaceuticals, Inc. Shares Popped

Is this meaningful or just another movement?

This Week in Biotech: 2 FDA Approvals and 3 Clinically Impressive Studies

Two biopharma stocks bask in an FDA approval while three others head higher following positive clinical data -- including a triple-digit percent gainer!

Sector Update: Healthcare Shares Flat to Lower Pre-Market; Pacira Up 5% on Phase 3 Trial Meeting End

Sector Update: Healthcare Shares Flat to Lower Pre-Market; Pacira Up 5% on Phase 3 Trial Meeting Endpoints

See More PCRX News...

Sector

Healthcare

Industry

Drugs

PACIRA PHARMACEUTICALS INC (PCRX) Description

PACIRA PHARMACEUTICALS INC Website: http://www.pacira.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks